A phase II study of NY-ESO-1 ISCOMATRIX vaccine and NY-ESO-1 ISCOMATRIX vaccine followed by recombinant fowlpox NY-ESO-1 (rF-NY-ESO-1) in patients with high-risk, resected melanoma


Year:

Session type:

Ji-Li Chen1, Sarah Pratap5, Ioannis Karydis5, Andrea Tarlton1, Amina Dawoodji1, Martha Woodward2, Paul Nathan4, Christian Ottensmeier3, Mark Middleton2, Vincenzo Cerundolo1

1Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, UK, 2Churchill Hospital, Oxford, UK, 3University of Southampton School of Medicine, UK, 4Mount Vernon Hospital, Northwood, UK, 5Churchill Hospital and Tumour Immunology Unit, University of Oxford, UK

Abstract

Background

Patients with Stage II-IV melanoma have a significant more than 20% at 5 years- risk of often incurable recurrence. The cancer-testis antigen NY-ESO-1 is frequently over-expressed in melanomas. Spontaneous combined antibody and